Technology Listings


145 Results Sort By:
HDAC Inhibitors for Managing Vascular Conditions and Diabetic Peripheral Neuropathies
Application Treatment of diabetic neuropathy using epigenetic modulators, histone deacetylase inhibitors (HDACis), to ameliorate or prevent vascular conditions and neuropathic pains by nerve damages. Key Benefits Reverses or protects against diabetes-induced nerve damages by direct injection of HDACi. Relatively low regulatory risk because many...
Published: 4/24/2020       Inventor(s): Young-Sup Yoon, Ji Woong Han, Hyunsuk Shim
Plant-Based Small Molecules for Treatment of MRSA Infections
Application Small molecule inhibitor of the accessory gene regulator (agr) for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections. Key Benefits Targeted system is non-essential for S. aureus growth, creating less selective pressure for resistance. Does not harm beneficial host bacteria. May potentially be used concomitantly...
Published: 4/23/2020       Inventor(s): Cassandra Quave, Akram Salam, Gina Porras Brenes, James Lyles
Therapeutic Compounds Inhibiting DUSP5 and DUSP6 for Cardiomyocyte Proliferation and Cardiac Regeneration
Application Therapeutics using siRNAs and small molecules to treat congenital heart defect and myocardial injuries. Key Benefits Reactivates cardiomyocyte (CM) cell replication, allowing regeneration of heart muscle after cardiac injuries. Therapeutic compounds may be administered for transient regeneration/repair of heart muscle after cardiac...
Published: 4/22/2020       Inventor(s): Ahsan Husain, Nawazish Naqvi
Small Molecule Inhibitor of Akt Activity for Lung Cancer Treatment
Application Mcl-1/Akt targeting small molecule with strong antitumor activity against lung cancer. Key Benefits Novel molecule. Novel target presents new path to lung cancer treatment. Potentially extend survival rate of lung cancer patients. Market Summary Lung cancer is the number one leading cause of death among cancer patients. Patients...
Published: 4/17/2020       Inventor(s): Xingming Deng
Chimeric Molecule for the Treatment of Depression
Application Small molecules for treating depression and/or depression associated with cancer/chemotherapy. Key Benefits Potentially a dual mechanism compound – working via monoamine reuptake inhibition and HDAC inhibition (epigenetic modification). Quicker acting compound compared to current therapies in the market. Works better than the...
Published: 4/17/2020       Inventor(s): Hyunsuk Shim, Huw Davies, Hyun Min Park, Yoon Hyeun Oum
Combination Therapy to Treat Pediatric Brain Tumor
Application Combination therapy (inhibition of STAT3 and YB-1) to treat medulloblastoma. Key Benefits Drug combination targets cancer stem cells. Increased apoptosis of cancer cells compared to current chemotherapeutic agents. Market Summary Medulloblastoma (MB) is the most common cancerous brain tumor that affects children and survival rates...
Published: 1/28/2020       Inventor(s): Tobey MacDonald, Anna Kenney, James Felker, Abhinav Dey
Reprogramming Human Urine Stem Cells into Vascular Tissue
Application System to generate vascular progenitor cells within naturally constructed (or formed) biomatrices from urine cells. Key Benefits Nearly limitless supply of source cells. Non-invasive method for harvesting source cells. Efficient endothelial cell generation with fewer steps and faster generation time than current standard for differentiating...
Published: 1/23/2020       Inventor(s): Young-Sup Yoon, Young-Doug Sohn, Sang-Ho Lee
Eradication of Pneumonococcal Carriage with Sodium Deoxycolate
Application Antibiotic use of sodium deoxycholate for preventing colonization with Streptococcus pneumoniae and treating pneumococcal infection. Key Benefits Effective against antibiotic-resistant pneumococcus. FDA-approved for use in humans. Safety already demonstrated in FDA trials for subcutaneous injection to dissolve fat deposits in humans. Market...
Published: 1/22/2020       Inventor(s): Jorge Vidal
Small Molecule for Treatment-Resistant Lung Cancer
Application Small molecule agonist for treating cancers involving KRAS mutations. Key Benefits Specifically targets mutant KRAS in non-small-cell lung carcinoma (NSCLC). Selective for mutant KRAS lung cancer cells over normal cells. Non-toxic to normal cells. Market Summary Lung cancer is the leading cause of cancer death in the US. Lung cancer...
Published: 1/14/2020       Inventor(s): Xingming Deng
Subunit-Selective NMDAR Antagonists for Treatment of Neurological Disorders
Application GluN2C/2D selective inhibitors that modulate N-methyl-D-aspartic acid receptors (NMDAR) in a subunit-selective manner for treatment of neurological disorders. Key Benefits Specifically targets NMDARs that contain the GluN2C/2D subunit. Higher potency and efficacy compared to previously reported GluN2C/2D-selective modulators. Market...
Published: 1/10/2020       Inventor(s): Yao Jing, Stephen Traynelis, Dennis Liotta
1 2 3 4 5 6 7 8 9 10 ...